Evidence map›Paper›PMID 25880113›Full record

ArticleVirology2015

Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein.

Xinsheng Zhang, Olivia L Wallace, Arban Domi, Kevin J Wright, Jonathan Driscoll, Omu Anzala, Eduard J Sanders, Anatoli Kamali, Etienne Karita, Susan Allen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Xinsheng ZhangAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA; Molecular and Cellular Biology Program, State University of New York, Brooklyn, NY, USA. Electronic address: xzhang@iavi.org.
Olivia L WallaceAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA.
Arban DomiAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA.
Kevin J WrightAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA.
Jonathan DriscollAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA.
Omu AnzalaKenya AIDS Vaccine Initiative (KAVI)-Institute of Clinical Research, Nairobi, Kenya.
Eduard J SandersCentre for Geographic Medicine Research, Kenya Medical Research Institute (KEMRI), Kilifi, Kenya & Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, UK.
Anatoli KamaliMRC/UVRI Uganda Virus Research Unit on AIDS, Masaka and Entebbe, Uganda.
Etienne KaritaProjet San Francisco, Kigali, Rwanda.
Susan AllenDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.
Pat FastDepartment of Medical Affairs, International AIDS Vaccine Initiative, NY, NY, USA.
Jill GilmourHuman Immunology Laboratory, International AIDS Vaccine Initiative, London, UK.
Matt A PriceDepartment of Medical Affairs, International AIDS Vaccine Initiative, NY, NY, USA; Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, USA.
Christopher L ParksAIDS Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Brooklyn, NY, USA; Molecular and Cellular Biology Program, State University of New York, Brooklyn, NY, USA.
International AIDS Vaccine Initiative · USEmory University · USInternational HIV/AIDS Alliance · GBKenya AIDS Vaccine Initiative · KEKenya Medical Research Institute · KEUganda Virus Research Institute · UG

Funding

Wellcome Trust 092654Wellcome Trust 203077
6 · The paper itself

Abstract

Serum was analyzed from 146 healthy adult volunteers in eastern Africa to evaluate measles virus (MV) and canine distemper virus (CDV) neutralizing antibody (nAb) prevalence and potency. MV plaque reduction neutralization test (PRNT) results indicated that all sera were positive for MV nAbs. Furthermore, the 50% neutralizing dose (ND50) for the majority of sera corresponded to antibody titers induced by MV vaccination. CDV nAbs titers were low and generally were detected in sera with high MV nAb titers. A mutant CDV was generated that was less sensitive to neutralization by human serum. The mutant virus genome had 10 nucleotide substitutions, which coded for single amino acid substitutions in the fusion (F) and hemagglutinin (H) glycoproteins and two substitutions in the large polymerase (L) protein. The H substitution occurred in a conserved region involved in receptor interactions among morbilliviruses, implying that this region is a target for cross-reactive neutralizing antibodies.

Indexed as

AdultAfrica, EasternAmino Acid SubstitutionAntibodies, NeutralizingAntibodies, ViralCross ReactionsDistemper Virus, CanineFemaleHealthy VolunteersHemagglutininsHumansMaleMeasles virusMiddle AgedMolecular Sequence DataNeutralization TestsAntibodies, NeutralizingAntibodies, ViralHemagglutininsViral ProteinsCanine distemper virusCross-neutralizationHemagglutininMeasles virusNeutralizing antibodyPlaque reduction neutralization testPre-existing immunity

Identifiers

PMID25880113
PMCPMC6624137
OpenAlexW2037494587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.